Abstract: Cardiovascular disease (CVD), the number one cause of death worldwide, has always been the focus of clinical and scientific research. Due to the high number of deaths each year, it is essential to find alternative therapies that are safe and effective with minimal side effects. Traditional Chinese medicine (TCM) has a long history of significant impact on the treatment of CVDs. The mode of action of natural active ingredients of drugs and the development of new drugs are currently hot topics in research on TCM. Astragalus membranaceus is a commonly used Chinese medicinal herb. Previous studies have shown that Astragalus membranaceus has anti-tumor properties and can regulate metabolism, enhance immunity, and strengthen the heart. Astragaloside IV (AS-IV) is the active ingredient of Astragalus membranaceus, which has a prominent role in cardiovascular diseases. AS-IV can protect against ischemic and hypoxic myocardial cell injury, inhibit myocardial hypertrophy and myocardial fibrosis, enhance myocardial contractility, improve diastolic dysfunction, alleviate vascular endothelial dysfunction, and promote angiogenesis. It can also regulate blood glucose and blood lipid levels and reduce the risk of cardiovascular diseases. In this paper, the mechanism of AS-IV intervention in cardiovascular diseases in recent years is reviewed in order to provide a reference for future research and new drug development.

Keywords: Astragalus membranaceus, astragaloside IV, traditional Chinese medicine, cardiovascular diseases, cardiomyocytes


中文翻译：

---

黄芪甲苷IV：一种有效的治疗心血管疾病的药物

【摘要】心血管疾病（CVD）是全球第一大死亡原因，一直是临床和科学研究的重点。由于每年的死亡人数很高，因此必须找到安全有效的副作用最小的替代疗法。中药（TCM）对CVD的治疗具有重大影响的悠久历史。药物天然活性成分的作用方式和新药的开发是当前中药研究的热点。黄芪是一种常用的中草药。以前的研究表明黄芪具有抗肿瘤特性，可以调节新陈代谢，增强免疫力并增强心脏。黄芪甲苷IV（AS-IV）是黄芪的活性成分，在心血管疾病中具有重要作用。AS-IV可以预防缺血性和缺氧性心肌细胞损伤，抑制心肌肥大和心肌纤维化，增强心肌收缩力，改善舒张功能障碍，减轻血管内皮功能障碍，并促进血管生成。它还可以调节血糖和血脂水平，降低心血管疾病的风险。本文综述了近年来AS-IV干预心血管疾病的机制，为今后的研究和新药开发提供参考。

关键字： 黄芪，黄芪甲苷，中药，心血管疾病，心肌细胞